Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · IEX Real-Time Price · USD
25.19
-0.57 (-2.21%)
Jul 5, 2024, 3:35 PM EDT - Market open
Spyre Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Spyre Therapeutics stock have an average target of 43, with a low estimate of 31 and a high estimate of 54. The average target predicts an increase of 70.70% from the current stock price of 25.19.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 13, 2024.
Analyst Ratings
The average analyst rating for SYRE stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 2 | 2 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $35 → $40 | Buy | Maintains | $35 → $40 | +58.79% | May 13, 2024 |
| BTIG | BTIG | Strong Buy Maintains $32 → $40 | Strong Buy | Maintains | $32 → $40 | +58.79% | May 10, 2024 |
| Baird | Baird | Buy Initiates $50 | Buy | Initiates | $50 | +98.49% | May 2, 2024 |
| Stifel | Stifel | Strong Buy Reiterates $36 → $54 | Strong Buy | Reiterates | $36 → $54 | +114.37% | Mar 26, 2024 |
| Wells Fargo | Wells Fargo | Hold → Buy Upgrades $12 → $35 | Hold → Buy | Upgrades | $12 → $35 | +38.94% | Mar 1, 2024 |
Financial Forecast
Revenue This Year
8.16M
from 886.00K
Increased by 820.99%
Revenue Next Year
6.12M
from 8.16M
Decreased by -25.00%
EPS This Year
-4.01
from -49.12
EPS Next Year
-3.97
from -4.01
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 42.0M | 31.5M | n/a | 1.1M | 1.1M |
| Avg | 8.2M | 6.1M | n/a | 255,000 | 339,997 |
| Low | n/a | n/a | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 4,640.4% | 286.0% | - | - | 311.8% |
| Avg | 821.0% | -25.0% | - | - | 33.3% |
| Low | - | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.52 | -2.71 | -3.78 | -1.23 | -1.42 |
| Avg | -4.01 | -3.97 | -4.83 | -4.88 | -4.00 |
| Low | -4.90 | -5.24 | -6.15 | -7.24 | -6.37 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.